Lupin Limited has informed the Exchange regarding a press release dated October 08, 2026, titled "Lupin Receives U.S. FDA Approval for Phytonadione Injectable Emulsion, USP".
Filed with NSE · ISIN INE326A01029 · · 2 pages · English
Summary by 6ix AI
The approval is for a single-dose prefilled syringe formulation, which is indicated for treating low blood clotting and vitamin K deficiency. This filing serves to inform the exchange and the public about the regulatory approval and its significance for Lupin's product portfolio.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
- Lupin Limited has informed the Exchange regarding a press release dated October 06, 2026, titled "Lupin Launches Formoflo-G® MDI, World s First Fixed-dose Triple Combination Drug for COPD Management".
- Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban Oral Suspension
- Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP
Earlier from Lupin
- Lupin Limited has informed the Exchange regarding a press release dated October 06, 2026, titled "Lupin Launches Formoflo-G® MDI, World s First Fixed-dose Triple Combination Drug for COPD Management".
- Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban Oral Suspension
- Lupin Limited Press Release Sep 28 2026
- Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP
- Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialize YUVEZZI™ in the European Union, the United Kingdom, Switzerland, Norway, and Iceland
Later from Lupin
All Lupin news releasesFollow Lupin into a list and get an email when it puts out news.
Follow Lupin